CA2283231C - Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation - Google Patents

Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation Download PDF

Info

Publication number
CA2283231C
CA2283231C CA002283231A CA2283231A CA2283231C CA 2283231 C CA2283231 C CA 2283231C CA 002283231 A CA002283231 A CA 002283231A CA 2283231 A CA2283231 A CA 2283231A CA 2283231 C CA2283231 C CA 2283231C
Authority
CA
Canada
Prior art keywords
tre
adenovirus
gene
cell
heterologous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002283231A
Other languages
English (en)
Other versions
CA2283231A1 (fr
Inventor
Daniel R. Henderson
De-Chao Yu
Henry G. Lamparski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CG Oncology Inc
Original Assignee
Cell Genesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/033,556 external-priority patent/US6432700B1/en
Application filed by Cell Genesys Inc filed Critical Cell Genesys Inc
Publication of CA2283231A1 publication Critical patent/CA2283231A1/fr
Application granted granted Critical
Publication of CA2283231C publication Critical patent/CA2283231C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002283231A 1997-03-03 1998-03-03 Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation Expired - Lifetime CA2283231C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US3976297P 1997-03-03 1997-03-03
US3976397P 1997-03-03 1997-03-03
US60/039,763 1997-03-03
US60/039,762 1997-03-03
US5452397P 1997-08-04 1997-08-04
US60/054,523 1997-08-04
US09/033,556 US6432700B1 (en) 1997-03-03 1998-03-02 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US09/033,556 1998-03-02
PCT/US1998/004080 WO1998039464A2 (fr) 1997-03-03 1998-03-03 Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation

Publications (2)

Publication Number Publication Date
CA2283231A1 CA2283231A1 (fr) 1998-09-11
CA2283231C true CA2283231C (fr) 2008-05-20

Family

ID=27488125

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002283231A Expired - Lifetime CA2283231C (fr) 1997-03-03 1998-03-03 Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation

Country Status (5)

Country Link
EP (1) EP1007715A2 (fr)
JP (1) JP2002514074A (fr)
AU (1) AU744725B2 (fr)
CA (1) CA2283231C (fr)
WO (1) WO1998039464A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE376062T1 (de) 1997-08-04 2007-11-15 Cell Genesys Inc Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
WO1999055365A1 (fr) 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Vecteurs adenoviraux avec proteines a deux types de genes de fibre
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
CA2342396A1 (fr) 1998-09-11 2000-03-23 Genvec, Inc. Adenovirus a ciblage altnernatif
US6406861B1 (en) 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US7691370B2 (en) 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
CZ301506B6 (cs) * 1998-10-15 2010-03-31 Canji, Inc. Selektivne se replikující rekombinantní virový vektor a zpusob jeho prípravy, farmaceutická formulace, zpusob usmrcení bunky s defektní dráhou, transformovaná bunka a promotor reagující na dráhu p53 a TGF-ß
WO2000022124A2 (fr) * 1998-10-15 2000-04-20 Canji, Inc. Procedes et compositions permettant d'induire une reponse antitumorale
US6649158B1 (en) 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
GB9906815D0 (en) * 1999-03-24 1999-05-19 Isrec Anti-neoplastic viral agents
CA2404060A1 (fr) * 2000-03-24 2001-10-04 Cell Genesys, Inc. Methodes de traitement de la neoplasie avec des adenovirus specifiques des cellules cibles associes a la chimiotherapie et a la radiotherapie
AU4764801A (en) * 2000-03-24 2001-10-08 Calydon Inc Cell-specific adenovirus vectors comprising an internal ribosome entry site
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6673614B2 (en) 2000-06-27 2004-01-06 Cell Genesys, Inc. Rapid methods and kits for detection and semi-quantitation of anti-adenovirus antibody
CA2424178A1 (fr) * 2000-09-30 2002-04-11 Diversa Corporation Manipulation de cellule entiere par mutagenese d'une partie substantielle d'un genome de depart, par combinaison de mutations et eventuellement par repetition
EP1377672A2 (fr) 2001-02-23 2004-01-07 Novartis AG Constructions de vecteurs
GB0117198D0 (en) * 2001-07-13 2001-09-05 Btg Int Ltd Anti-neoplastic viral agents
WO2004042025A2 (fr) 2002-11-01 2004-05-21 Cell Genesys, Inc. Vecteur d'adenovirus specifique des cellules comprenant un promoteur specifique de ebv
CA2516652A1 (fr) * 2003-02-24 2005-01-27 Cell Genesys, Inc. Systeme pour la commande externe de la reproduction d'un virus oncolytique
US7482156B2 (en) 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
WO2011043719A1 (fr) * 2009-10-05 2011-04-14 Ya-Fang Mei Réplication de vecteurs viraux pour thérapie génique
JP7208492B2 (ja) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド 併用療法によって固形腫瘍又はリンパ系腫瘍を処置する方法
WO2018191654A1 (fr) 2017-04-14 2018-10-18 Cold Genesys, Inc. Méthodes de traitement du cancer de la vessie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337209B1 (en) * 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
GB9216851D0 (en) * 1992-08-07 1992-09-23 Univ Manitoba Dna sequences of rat probasin gene
US5698443A (en) * 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
CA2206179C (fr) * 1994-11-28 2007-10-23 Genetic Therapy, Inc. Vecteurs de replication a specificite tissulaire
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors

Also Published As

Publication number Publication date
WO1998039464A2 (fr) 1998-09-11
JP2002514074A (ja) 2002-05-14
WO1998039464A3 (fr) 1999-01-07
EP1007715A2 (fr) 2000-06-14
AU6345098A (en) 1998-09-22
WO1998039464A8 (fr) 1999-04-01
AU744725B2 (en) 2002-02-28
CA2283231A1 (fr) 1998-09-11

Similar Documents

Publication Publication Date Title
CA2283231C (fr) Vecteurs d'adenovirus contenant des elements heterologues regulateurs de transcription, et leur procede d'utilisation
EP0972063B1 (fr) VECTEURS D'ADENOVIRUS SPECIFIQUES DE CELLULES EXPRIMANT LA FETOPROTEINE $g(a), ET LEURS MODES D'UTILISATION
AU762940B2 (en) Adenovirus vectors containing cell status-specific response elements and methods of use thereof
EP1017836B1 (fr) Vecteurs d'adenovirus specifiques de cellules exprimant le recepteur de l'androgene et leurs methodes d'utilisation
EP1141363B1 (fr) Vecteurs et transgenes ayant des elements regulateurs pour l'administration de genes dans le foie
US20030044383A1 (en) Tissue specific adenoviral vectors
WO1998039467A2 (fr) Vecteurs d'adenovirus specifiques de cellules exprimant l'antigene carcino-embrionnaire et leurs methodes d'utilisation
US7001764B2 (en) Compositions comprising tissue specific adenoviral vectors
US7011976B1 (en) Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
AU2003252891B2 (en) Adenovirus vectors containing cell status-specific response elements and methods of use thereof
EP1905837A1 (fr) Vecteurs d'adénovirus contenant des éléments hétérologues régulateurs de la transcription et procédés les utilisant
US20020068049A1 (en) Tissue specific adenoviral vectors
AU745600B2 (en) Adenovirus vectors specific for cells expressing carcinoembryonic antigen and methods of use thereof
US20060024273A1 (en) Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US20060165658A1 (en) Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
EP1918380A2 (fr) Vecteurs d'adénovirus spécifiques de cellules exprimant la fétoprotéine alfa, et leur modes d'utilisation
EP0968298A2 (fr) Vecteurs d'adenovirus specifiques de cellules exprimant l'antigene carcino-embrionnaire et leurs methodes d'utilisation

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180305